Heart failure & cardiomyopathies
Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis
Performance · T2 mapping to differentiate AL from ATTRResult — go to the resultAUC 0.86 95% CI 0.74–0.94Authors' conclusion
ECV differentiates cardiac amyloidosis from other causes of LVH. T2 mapping combined with LGE differentiates AL from ATTR amyloidosis with high accuracy on a patient level.
Study context
- Population
- Patients with cardiac amyloidosis (AL or ATTR) and controls with other causes of LVH53 with cardiac amyloidosis
- Participants
- 75 patients
- Comparison
- Cardiovascular magnetic resonance (CMR) parameters for AL vs ATTR amyloidosis and vs other causes of LVH
- ALn = 20
- ATTRn = 33
- LVHn = 22reference
- Outcome
- Differentiation of AL and ATTR amyloidosis by CMR parameters
Methodological detailsretrospective
- Retrospective
Performance
T2 mapping to differentiate AL from ATTR
AUC
0.86
95% CI 0.74–0.94
P < 0.001
By group
As reported in the abstract
Further findings
| Outcome | AL | ATTR | LVH | AUC (95% CI) | P value | |
|---|---|---|---|---|---|---|
| ECV to differentiate cardiac amyloidosis from controlsAL vs LVH · cardiac amyloidosis (AL + ATTR) vs controls; cut-off >30% | 0.97 (0.89–0.99) | P < 0.0001 | ||||
| Subendocardial LGEAL vs ATTR | 50% | 15% | Not reported in the abstract | P = 0.002 | LVH: not reported in the abstract | |
| Transmural LGEATTR vs AL | 10% | 70% | Not reported in the abstract | P < 0.001 | LVH: not reported in the abstract | |
| T2 mapping plus LGE patterns to differentiate AL from ATTRAL vs ATTR | 0.96 (0.86–0.99) | P = 0.05 |
Original publication
Parametric mapping using cardiovascular magnetic resonance for the differentiation of light chain amyloidosis and transthyretin-related amyloidosis. Eur Heart J Cardiovasc Imaging. Published 24 June 2024. doi:10.
Summarised from the published abstract; every number is checked against it